Skip to main content

Advertisement

SpringerLink
Log in

Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma

  • Short Communication
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Leukocytoclastic vasculitis (LV) is a systemic inflammatory disorder involving mostly the small vessels. It is characterised by segmental angiocentric neutrophilic inflammation, endothelial cell damage and fibrinoid necrosis. LV is related to a variety of clinical disorders including cryoglobulinemia and, very rarely, multiple myeloma (MM), among many others. The development of LV in patients with MM has been linked to cryoglobulinemia, infections, drugs and paraneoplasia. It has been speculated that myeloma patients with a poorer prognosis and progressive disease are more prone to develop LV. Thalidomide is a rediscovered old drug with anti-angiogenic, immunomodulatory and anti-inflammatory properties. It is highly effective in the treatment of MM and other clinical disorders such as leprosy, various cancers, graft-versus-host disease and autoimmune diseases. We report here a female patient with Durie–Salmon stage IIA MM who initially presented with cryoglobulinemia and LV. LV in this patient was primarily considered to be the result of progressive cryoglobulinemia, which was closely associated with MM. She was successfully managed with thalidomide and dexamethasone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768–769

    Article  CAS  PubMed  Google Scholar 

  2. Barnhill RL, Doll NJ, Millikan LE et al (1984) Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 11:814–819

    CAS  PubMed  Google Scholar 

  3. Bayer-Garner IB, Smoller BR (2003) Leukocytoclastic (small vessel) vasculitis in multiple myeloma. Clin Exp Dermatol 28:521–524

    Article  CAS  PubMed  Google Scholar 

  4. Bayer-Garner IB, Smoller BR (2003) The spectrum of cutaneous disease in multiple myeloma. J Am Acad Dermatol 48:497–507

    Article  PubMed  Google Scholar 

  5. D’Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082–4085

    CAS  PubMed  Google Scholar 

  6. Damiano JS, Cress AE, Hazlehurst LA et al (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658–1667

    CAS  PubMed  Google Scholar 

  7. Dammacco F, Sansonno D, Piccoli C et al (2001) The cryoglobulins: an overview. Eur J Clin Investig 31:628–638

    Article  CAS  Google Scholar 

  8. Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210–216

    Article  CAS  PubMed  Google Scholar 

  9. Faure M, Thivolet J, Gaucherand M (1980) Inhibition of polymorphonuclear leukocytes chemotaxis by thalidomide. Arch Dermatol Res 269:275–280

    Article  CAS  PubMed  Google Scholar 

  10. Garcia-Porrua C, Gonzales-Gay MA (1998) Cutaneous vasculitis as paraneoplastic syndrome in adults. Arthritis Rheum 41:1133–1136

    Article  CAS  PubMed  Google Scholar 

  11. Geitz H, Handt S, Zwingerberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213–221

    Article  CAS  PubMed  Google Scholar 

  12. Hamuryudan V, Mat C, Saip S et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of Behçet’s syndrome: a randomized, double-blind, placebo controlled trial. Ann Intern Med 128:443–459

    CAS  PubMed  Google Scholar 

  13. Haslett PA, Corral LG, Albert M et al (1998) Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885–1892

    Article  CAS  PubMed  Google Scholar 

  14. Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943–2950

    CAS  PubMed  Google Scholar 

  15. Highet AS (1980) Urticarial vasculitis and IgA myeloma. Br J Dermatol 102:355–357

    CAS  PubMed  Google Scholar 

  16. Kois JM, Sexton FM, Lookingbill DP et al (1991) Cutaneous manifestations of multiple myeloma. Arch Dermatol 127:69–74

    Article  CAS  PubMed  Google Scholar 

  17. Li X, Liu X, Wang J et al (2003) Thalidomide down-regulates the expression of VEGF and b-FGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 23:2481–2487

    CAS  PubMed  Google Scholar 

  18. Lotti T, Ghersetich I, Comacchi C et al (1998) Cutaneous small-vessel vasculitis. J Am Acad Dermatol 39:667–687

    CAS  PubMed  Google Scholar 

  19. Lucas E, Martinez A, Guerao MR et al (1997) Hypersensitivity vasculitis as the first manifestation of a multiple myeloma. An Med Interna 14:374–375

    Google Scholar 

  20. McMillen JJ, Krueger SK, Dyer GA (1986) Leukocytoclastic vasculitis in association with immunoglobulin A myeloma. Ann Intern Med 105:709–710

    CAS  PubMed  Google Scholar 

  21. Means RT, Greer JP, Sergent JS et al (1987) Leukocytoclastic vasculitis and multiple myeloma. Ann Intern Med 106:329–331

    Google Scholar 

  22. Mileshkin L, Biagi JJ, Mitchell P et al (2003) A multi-center phase II trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102:69–77

    Article  CAS  PubMed  Google Scholar 

  23. Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525–4530

    Article  CAS  PubMed  Google Scholar 

  24. Moehler TM, Neben K, Benner A et al (2001) Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98:3846–3848

    Article  CAS  PubMed  Google Scholar 

  25. Moriera AL, Sampaio EP, Zmuidzinas A et al (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675–1680

    Article  PubMed  Google Scholar 

  26. Neben K, Moehler T, Kraemer A et al (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115:605–608

    Article  CAS  PubMed  Google Scholar 

  27. Neben K, Moehler T, Benner A et al (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8:3377–3382

    CAS  PubMed  Google Scholar 

  28. Sanchez NB, Canedo IF, Garcia-Patos PE et al (2004) Paraneoplastic vasculitis associated with multiple myeloma. J Eur Acad Dermatol Venereol 18:731–735

    Article  CAS  PubMed  Google Scholar 

  29. Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571

    Article  CAS  PubMed  Google Scholar 

  30. Turk BE, Jiang H, Liu JO (1996) Binding of thalidomide to alpha 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A 93:7552–7556

    Article  CAS  PubMed  Google Scholar 

  31. Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16–19

    Article  CAS  PubMed  Google Scholar 

  32. Witzens M, Moehler T, Neben K et al (2004) Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Ann Hematol 83:467–470

    Article  PubMed  Google Scholar 

  33. Yabu T, Tomimoto H, Taguchi Y et al (2005) Thalidomide-induced anti-angiogenic action is mediated by ceramide through depletion of VEGF receptors, and antagonized by sphingosine-1-phosphate. Blood (prepublished online March 1, 2005; DOI 10.1182/blood-2004-09-3679)

Download references

Acknowledgements

We thank Prof. H.M. Moutsopoulos (Athens, Greece) for his help in the management of this patient.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Haematology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    M. Cem Ar, Teoman Soysal & Birsen Ulku

  2. Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    Gulen Hatemi & Hasan Yazici

  3. Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    Ayse Salihoglu

Authors
  1. M. Cem Ar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teoman Soysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gulen Hatemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayse Salihoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hasan Yazici
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Birsen Ulku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Cem Ar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cem Ar, M., Soysal, T., Hatemi, G. et al. Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Ann Hematol 84, 609–613 (2005). https://doi.org/10.1007/s00277-005-1053-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1053-1

Keywords

Search

Navigation